Stock Movers: GameStop, BioNTech, Oracle

On this edition of Stock Movers: - GameStop (GME) shares plummeted today. The company had two developments. First, GameStop is focused on growing its trading card business. That is according to CEO Ryan Cohen. The business of Pokémon and sports trading cards 'is in line with our heritage,' Cohen said. 'It fits our trade-in model, it appeals to our core customer base and it's deeply embedded in physical retail.' The second development is GameStop plans to offer $1.75 billion worth of convertible bonds, which would make the video-game retailer one of the year's biggest issuers of the equity-linked securities. - BioNTech (BNTX) agreed to buy former Covid vaccine rival CureVac NV (CVAC) for about $1.25 billion in an all-stock transaction that will boost its growing oncology business. CureVac investors will get approximately $5.46 in BioNTech shares for each CureVac one, the companies said Thursday. The price represents a 34% premium to CureVac's closing share price on Wednesday. CureVac shareholders will own between 4% and 6% of BioNTech once the deal closes. Shares of BioNTech are flat while CureVac shares surged. - Oracle (ORCL) shares soared to a record high after the software maker projected a 70% gain in cloud infrastructure sales this fiscal year, giving a bullish outlook for the closely watched business. The company, long known for its database software, has been gaining traction in its effort to become a major player in the business of cloud computing — renting out computing power and storage — by targeting clients focused on artificial intelligence work. Earlier this year, it announced a joint venture dubbed Stargate to provide OpenAI with massive sums of computing power.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Upturn

2 days ago

• Business Upturn

Axiom Intelligence Acquisition Corp 1 Announces Completion of $200 Million Initial Public Offering

New York, New York, June 20, 2025 (GLOBE NEWSWIRE) — Axiom Intelligence Acquisition Corp 1 (NASDAQ:AXINU) (the 'Company') today announced the closing of its initial public offering of 20,000,000 units, which includes 2,500,000 units sold pursuant to the partial exercise of the underwriters' over-allotment option. The offering was priced at $10.00 per unit, resulting in gross proceeds of $200,000,000. The Company's units commenced trading on the Nasdaq Global Market ('Nasdaq') under the symbol 'AXINU' on June 18, 2025. Each unit issued in the offering consists of one Class A ordinary share of the Company and one right to receive one tenth (1/10) of one Class A ordinary share upon the consummation of the Company's initial business combination. Once the securities comprising the units begin separate trading, the Class A ordinary shares and rights are expected to be listed on Nasdaq under the symbols 'AXIN' and 'AXINR,' respectively. The Company is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an initial business combination target in any stage of its corporate evolution or in any industry or sector, the Company intends to focus its initial search on companies in the European infrastructure industry. The Company's management team is led by Richard Dodd, its Executive Chairman, Douglas Ward, its Chief Executive Officer, Daniel Mamadou-Blanco, its President, Robert Dilling, its Chief Financial Officer, and Chris Ackermann, its Chief Operating Officer. Dr. Claire Handby, Steven Leighton and Christopher Ellis are the Company's independent directors and Sankalp Shangari and Wendy Li are its senior advisers. Cohen & Company Capital Markets, a division of J.V.B. Financial Group, LLC, acted as the lead book-running manager for the offering. Seaport Global Securities LLC acted as joint book-runner. A registration statement relating to the units and the underlying securities was declared effective by the Securities and Exchange Commission on June 17, 2025. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering was made only by means of a prospectus, copies of which may be obtained from Cohen & Company Capital Markets, 3 Columbus Circle, 24th Floor, New York, NY 10019, Attention: Prospectus Department, or by email at: [email protected]. Copies of the registration statement can be accessed for free through the SEC's website at Forward-Looking Statements This press release contains statements that constitute 'forward-looking statements,' including with respect to the anticipated use of the net proceeds of the offering and the Company's search for an initial business combination. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and final prospectus for the offering filed with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this press release, except as required by law. Contact Information: Axiom Intelligence Acquisition Corp 1Richard Dodd, Executive Chairman / Doug Ward, Chief Executive Officer [email protected] +44 20 3973 7928

Yahoo

2 days ago

• Yahoo

CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech

Shares of CureVac N.V. CVAC have skyrocketed 40.8% in a month after the company signed a definitive agreement to be acquired by BioNTech SE BNTX in an all-stock transaction last week. Per the agreement, each CVAC share will be exchanged for approximately $5.46 worth of BNTX American Depositary Shares (ADS), implying a total equity value of around $1.25 billion for CureVac. The consideration per ADS represents a premium of 55% to CVAC's three-month volume-weighted average price of approximately $3.53 as of June 11, 2025. Subject to the closing of the transaction, CureVac shareholders are expected to own between 4% and 6% of BioNTech. The closing of the transaction, expected in 2025, is based on the fulfillment of certain customary closing conditions and required regulatory approvals. Year to date, shares of CureVac have surged 61% against the industry's 4.8% decline. Image Source: Zacks Investment Research The acquisition of CureVac will help BioNTech enhance its capabilities in advancing investigational mRNA-based cancer immunotherapies by expanding its research, development, manufacturing and commercialization infrastructure. It complements BioNTech's existing strengths in mRNA design, delivery technologies and production. BNTX's Comirnaty is the first approved mRNA-based vaccine for COVID-19, which was developed in collaboration with Pfizer. Strategically, the deal will allow BioNTech to expand beyond its existing oncology pipeline and focus on its newer programs across several tumor types, including key assets like its mRNA-based cancer candidates and BNT327, a PD-L1xVEGF-A bispecific antibody. We remind the investors that earlier in June, BioNTech signed a strategic collaboration agreement with Bristol Myers BMY for the global co-development and co-commercialization of BNTX's BNT327, as monotherapy and in combinations, across numerous solid tumor types. BMY will pay $1.5 billion upfront, with $2 billion in additional payments through 2028 and up to $7.6 billion in milestones. BioNTech and Bristol Myers will equally share costs and profits. BNT327 is in late-stage, potentially registrational clinical studies for two different lung cancer indications. Another phase III study evaluating the candidate in triple-negative breast cancer is planned to start by the end of 2025. Early data show promising synergy in targeting two key cancer pathways. CureVac N.V. price-consensus-chart | CureVac N.V. Quote CureVac currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Immunocore IMCR, currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. In the past 60 days, loss per share estimates for Immunocore's 2025 have improved from $1.50 to 86 cents. Loss per share estimates for 2026 have narrowed from $1.68 to $1.33 during the same period. IMCR stock has gained 7.5% year to date. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report CureVac N.V. (CVAC) : Free Stock Analysis Report Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio

Yahoo

3 days ago

• Yahoo

Nintendo Switch 2 Restock Finally Makes Console Available to Buy

A fresh Nintendo Switch 2 restock has finally made the console available to buy again, with buyers finding that two stores have refreshed their inventory. The Switch 2 has been selling like hotcakes since it launched earlier this month, as buyers snapped up the long-awaited hardware. While many stores are still listing it as unavailable to purchase, buyers have noted that two stores have availability. However, given how quickly the console is selling out across the U.S., you'll need to be quick to purchase the system. The Switch 2's restocked units are available for purchase in Costco and in select GameStop stores. GameStop doesn't have units currently available online, though some stores currently have stock. Prospective buyers can search for their local store to see if any are available. Buy the Nintendo Switch 2 at Costco See if the Switch 2 is available at your nearby GameStop Costco purchases are only available with a membership, which is available for $65 a year. Nintendo managed to supply a lot of demand for the Switch 2 at launch, with it smashing sales records by shifting 3.5 million units within its first four days. Due to the overwhelming popularity of the console, it's become difficult for buyers to get their hands on one post-launch. Hopefully, more restocks will happen sooner rather than later. The post Nintendo Switch 2 Restock Finally Makes Console Available to Buy appeared first on PlayStation LifeStyle.